TG Therapeutics Inc expected to post a loss of 5 cents a share - Earnings Preview

TG Therapeutics

26/07/2024 15:54

* TG Therapeutics Inc  TGTX.OQ   TGTX.O  is expected to show
a
rise in quarterly revenue when it reports  results on July 30
(estimated) for the period ending June 30 2024
    * The Morrisville North Carolina-based  company is expected
to
report a 309.9% increase in revenue to $65.893 million from
$16.07 million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for TG Therapeutics Inc is
for a
loss of 5 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for TG
Therapeutics
Inc is $34.50​, above​ its last closing price of $19.98. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.02       -0.04      -0.07     Missed  -96
 Dec. 31 2024  -0.12       -0.10      -0.10     Met     4.1
 Jan. 1 0001   0.05        0.12       0.73      Beat    530.9​
 Jun. 30 2023  -0.24       -0.25      -0.34     Missed  -36.7
 ​​Jan.        -0.38       -0.37      -0.28     Beat    23.7
 1 0001                                                 
 Dec. 31 2022  -0.28       -0.26      -0.39     Missed  -50​
 Sep. 30 2022  -0.33       -0.34      -0.26     Beat    23.9
 Jan. 1 0001   -0.57       -0.51      -0.30     Beat    41.2
 This summary was machine generated July 26 at 14:54 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)